Literature DB >> 9521242

Factors determining the therapeutic window for stroke.

J A Zivin1.   

Abstract

The duration of the window to treat acute cerebral ischemia has become an important question since the first effective drug for stroke victims has become available. Statistical analysis of relevant animal studies suggests that irreversible focal injury begins within a few minutes and is complete within about 6 hours. There will be substantial difficulties in attempting to obtain accurate estimates of the duration of ischemia that causes permanent damage in patients unless technical obstacles are overcome. Empirical estimates of the therapeutic window for stroke can be obtained from properly designed clinical trials, but optimal care will continue to necessitate urgent treatment.

Entities:  

Mesh:

Year:  1998        PMID: 9521242     DOI: 10.1212/wnl.50.3.599

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  22 in total

1.  Glyceraldehyde-3-phosphate dehydrogenase versus toluidine blue as a marker for infarct volume estimation following permanent middle cerebral artery occlusion in mice.

Authors:  Bettina H Clausen; Kate L Lambertsen; Bente Finsen
Journal:  Exp Brain Res       Date:  2006-05-24       Impact factor: 1.972

Review 2.  Neuroprotection for ischemic stroke: two decades of success and failure.

Authors:  Yu Dennis Cheng; Lama Al-Khoury; Justin A Zivin
Journal:  NeuroRx       Date:  2004-01

3.  Two-hour improvement of patients in the National Institute of Neurological Disorders and Stroke trials and prediction of final outcome.

Authors:  Thomas M Hemmen; Karin Ernstrom; Rema Raman
Journal:  Stroke       Date:  2011-08-25       Impact factor: 7.914

4.  Assessment of baseline hemodynamic parameters within infarct progression areas in acute stroke patients using perfusion-weighted MRI.

Authors:  Thomas Ritzenthaler; Tae-Hee Cho; Marlène Wiart; Julien Berthiller; Leif Østergaard; Marc Hermier; Laurent Derex; Yves Berthezène; Norbert Nighoghossian
Journal:  Neuroradiology       Date:  2010-11-27       Impact factor: 2.804

5.  Brain protection from stroke with intravenous TNFα decoy receptor-Trojan horse fusion protein.

Authors:  Rachita K Sumbria; Ruben J Boado; William M Pardridge
Journal:  J Cereb Blood Flow Metab       Date:  2012-06-20       Impact factor: 6.200

Review 6.  Targeted delivery of therapeutics to endothelium.

Authors:  Eric Simone; Bi-Sen Ding; Vladimir Muzykantov
Journal:  Cell Tissue Res       Date:  2008-09-25       Impact factor: 5.249

7.  Good clinical outcome after ischemic stroke with successful revascularization is time-dependent.

Authors:  P Khatri; T Abruzzo; S D Yeatts; C Nichols; J P Broderick; T A Tomsick
Journal:  Neurology       Date:  2009-09-29       Impact factor: 9.910

8.  Association between cytochrome P450 promoter polymorphisms and ischemic stroke.

Authors:  Su Kang Kim; Sung-Vin Yim; Byung-Cheol Lee
Journal:  Exp Ther Med       Date:  2011-11-22       Impact factor: 2.447

9.  Thyroid hormone modulates neuroglobin and cytoglobin in rat brain.

Authors:  Kelen Carneiro Oliveira; Rodrigo Rodrigues da Conceição; Gisele Constantinov Piedade; Janaina Sena de Souza; Monica Akemi Sato; Rui Monteiro de Barros Maciel; Gisele Giannocco
Journal:  Metab Brain Dis       Date:  2015-09-03       Impact factor: 3.584

Review 10.  Management of hypertension in the setting of acute ischemic stroke.

Authors:  Laura Heitsch; Edward C Jauch
Journal:  Curr Hypertens Rep       Date:  2007-12       Impact factor: 5.369

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.